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S U M M A R Y
Japanese encephalitis (JE) is prevalent throughout eastern and southern Asia and the Paciﬁc Rim. It is
caused by the JE virus (JEV), which belongs to the family Flaviviridae. Despite the importance of JE, little is
known about its pathogenesis. The role of oxidative stress in the pathogenesis of viral infections has led
to increased interest in its role in JEV infections. This review focuses mainly on the role of oxidative stress
in the pathogenesis of JEV infection and the antiviral effect of antioxidant agents in inhibiting JEV
production. First, this review summarizes the pathogenesis of JE. The pathological changes include
neuronal death, astrocyte activation, and microglial proliferation. Second, the relationship between
oxidative stress and JEV infection is explored. JEV infection induces the generation of oxidants and
exhausts the supply of antioxidants, which activates speciﬁc signaling pathways. Finally, the therapeutic
efﬁcacy of a variety of antioxidants as antiviral agents, including minocycline, arctigenin, fenoﬁbrate,
and curcumin, was studied. In conclusion, antioxidants are likely to be developed into antiviral agents for
the treatment of JE.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Japanese encephalitis (JE) is prevalent throughout eastern and
southern Asia and the Paciﬁc Rim, with an estimated 50 000 cases
and 15 000 deaths annually.1 In humans, JE can range from a mild
febrile illness to severe encephalitis, including seizures, a polio-like
illness, and a variety of movement disorders.2 In fatal cases of JE,
pathological changes are seen in various parts of the nervous
system, including a severe degree of vascular congestion, cerebral
edema, neuron death, astrocyte activation, and microglial prolif-
eration.1 The etiologic agent, Japanese encephalitis virus (JEV),
belongs to the family Flaviviridae and can be transmitted between* Corresponding author. Tel./Fax: +86 23 68752229.
E-mail addresses: 442653949@qq.com (Z. Chen),
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1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).animal and human hosts by Culex species of mosquitoes. Although
vaccination is the most viable option to control JE, affordable
vaccines are still not widely available.3 Little is known about the
pathogenesis of human JEV infection, including the mechanism of
its spread to the central nervous system (CNS) and viral tropism
within the brain.4
JEV is a single-stranded, positive-sense RNA virus that encodes
three structural proteins (capsid protein (C), precursor to the
membrane protein (PrM), and envelope protein (E)) and seven
nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and
NS5). JEV might have a peripheral replication cycle, since in vitro
studies have revealed that peripheral blood mononuclear cells
(PBMCs), including monocytes and macrophages, can be infected
and invade the CNS via the antipodal transport of virions or
through vascular endothelial cells. Neuronal apoptosis is one of the
hallmarks of neurodegenerative infections and many ﬂavivirusesciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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and in rodent models in vivo.5,6 JEV NS2B–NS3 protease was found
to reduce the reduction of mitochondrial membrane potential and
stimulate the release of mitochondrial cytochrome C, which
induces mitochondria-mediated apoptosis by activating the ASK1-
p38 mitogen-activated protein kinase (MAPK) signaling pathway-
mediated apoptosis.7 JEV has also been shown to cause neuronal
loss due to the rough endoplasmic reticulum stress pathway.8,9
Viral tropism in neural progenitor stem cells (NPSCs) and
immature neurons has also been reported in experimental models
of JEV infection.10–12 However, mature neurons become resistant
to JEV-induced apoptosis due to the increased neuronal expression
of cellular inhibitors of apoptosis, such as Bcl-2 and Bcl-x.13
In addition to neurons, astrocytes and microglial cells can also
be infected by JEV.14,74 Astrocytes form part of the blood–brain
barrier (BBB) and play multiple roles in the CNS, including
maintaining homeostasis by storing energy in the form of glycogen
and producing enzymes that exert detoxiﬁcation effects. In a
recent comparative study of human and mouse models, prominent
astrocyte activation, particularly in areas of neuronal damage, was
seen with JEV infection.15 Microglial cells are the resident
macrophages of the CNS and as such might serve as a reservoir
for the virus.16 Ghoshal et al. reported that the levels of various
proinﬂammatory mediators, such as inducible nitric oxide
synthase (iNOS), cyclooxygenase 2 (Cox-2), interleukin 6 (IL-6),
IL-1b, tumor necrosis factor alpha (TNF-a), and monocyte
chemoattractant protein 1 (MCP-1), were signiﬁcantly elevated
in microglial cells following JEV infection.17 Activation of micro-
glial cells might play a signiﬁcant role in inducing neuronal cell
death by stimulating the production of proinﬂammatory media-
tors.
The growing number of reviews describing a role for oxidative
stress in the pathogenesis of viral infections has led to increased
interest in the role of oxidative stress in JEV infections.18 Reactive
oxygen species (ROS)-mediated neuronal cell death, including
neurons and glial cells, has been observed in vitro after JEV
infection.19 This is highly speciﬁc to neuronal cells and involves an
unidentiﬁed receptor-mediated death-signaling pathway. In order
to avoid ROS-mediated damage caused by virus infection,
antioxidants in the host cell react with elevated oxidants and
superoxides and inhibit virus production. Such agents could not
only alleviate disease symptoms but also decrease the long-term
effects of chronic oxidative stress.20,21 This review focuses mainlyTable 1
Characteristics of oxidative stress in JEV-infected cells and tissues
Cell/tissue Stimulus/condition 
Human pro-monocyte cells Infected with JEV at MOIs of 0.1 
after 24, 48, and 72 h incubation
Corpus striatum, frontal cortex,
thalamus, and midbrain of rats
Inoculated intracerebrally with 3
PFU JEV
Neuro2a (N2a) cells Infected with JEV at MOI of 5 for
Forebrain neurons of rats Inoculated intracerebrally with 3
PFU JEV on days 3, 6, 10, and 20
Rat glial cultures (85% astrocytes,
7% microglia and others)
Infected with JEV at MOI of 10 
Mouse neuroblastoma N18 cells Infected with JEV at MOI of 5 
Human astroglial cell lines (U87 and
SVG cell lines)
Incubated with JEV at MOI of 5 f
N18 and human neuronal NT-2 cells Incubated with UV-inactivated JE
JEV, Japanese encephalitis virus; MOI, multiplicity of infection; TRX, thioredoxin; PFU
dismutase; CAT, catalase; GPx, glutathione peroxidase; GSH, glutathione; ROS, reactive o
LDH, lactate dehydrogenase; IL, interleukin; EAAT-1, astrocytic transporters GLT-1; EAA
monocyte chemoattractant protein-1; MIG, membrane immunoglobulin; RANTES, regu
a # = downregulated, " = upregulated, with respect to normal controls.
b (A) ROS, IP-10, MCP-1, MIG, RANTES, EAAT-1 and EAAT-2 levels higher in U87 thaon the role of oxidative stress in the pathogenesis of JEV infection
and the potential of antioxidants for the treatment of JEV infection.
2. Oxidative stress and JEV infection
Intracellular redox balance is the result of a dynamic
equilibrium between oxidant and antioxidant molecules. Oxida-
tive stress occurs when the production of ROS exceeds the capacity
of cellular antioxidant defenses to remove these toxic species.
Superﬂuous ROS are capable of causing oxidative damage to
macromolecules, leading to lipid peroxidation and the oxidation of
amino acid side chains and polypeptide backbones, resulting in
protein fragmentation and DNA damage.22–24 Growing evidence
has suggested a close correlation between oxidative stress and
viral infectious disease.25 The elevated oxidants induced by viral
infection include nitric oxide radicals (NO), superoxide anions
(O2
), hydroxy radicals (OH) and their by-products (such as
hydrogen peroxide, H2O2), which may all contribute to viral
pathogenesis, the modulation of cellular responses, and the
regulation of viral replication and the host defense.26,27
JEV infection can lead to death in approximately 2030% of
infected patients.28,29 After a mosquito bite, the virus crosses the
BBB to the CNS; the resulting neuronal apoptosis and inﬂammation
are generally attributed to JEV-induced cytopathology.30 However,
the extent of cell injury that can be accredited to viral
cytopathology remains unclear.17,31 Early in 2002, Liao et al. found
that JEV infection induced the generation of superoxide anions
(O2
) in rat cortical glial cells.32 Consistent with this, a subsequent
study by Srivastava et al. revealed that free radicals, such as ROS
and peroxynitrite (OONO), were increased in acute JE rat
models.18 After JEV infection, the elevation of O2
 in the host
cell leads to the activation of host superoxide dismutase (SOD) in
an attempt to suppress the elevated levels of superoxide.33 H2O2,
the product of the reaction between O2
 and SOD, can react with
O2
 again if it is not rapidly cleared. The OH produced by the
reaction between O2
 and H2O2 then leads to host cell apoptosis.
Table 1 summarizes some of the key characteristics of oxidative
stress in JEV-infected cells and tissues, compiled from different
studies.
Additional important mechanisms regarding JEV-induced
apoptosis have been reported, including the initiation of endo-
plasmic reticulum stress, generation of ROS, and activation of
nuclear factor kappa B (NF-kB).19 Furthermore, elevated ROS can
react to form peroxynitrite, which triggers the loss of adenosinePhenotypea Ref.
and 1 # TRX 35
  106 " MDA, Mn-SOD; # CAT, GPx, and GSH 33
 24 h " ROS 56
  106 " ROS and OONO on 6 DPI; NO on 10
DPI; # ROS on 20 DPI
18
" Superoxide anion; NO; Mn-SOD 32
"ROS; LDH 31
or 72h "ROS, IL-6, IL-1b, IL-8; TRX,
ceruloplasmin; EAAT-1 and EAAT-2b
74
V "ROS 19
, plaque-forming unit; MDA, malondialdehyde; Mn-SOD, manganese superoxide
xygen species; OONO, peroxynitrite; DPI, days post inoculation; NO, nitric oxide;
T-2, astrocytic transporters GLAST; IP-10, interferon inducible protein 10; MCP-1,
lated on activation, normal T cell expressed and secreted; UV, ultraviolet.
n in SVG cells. (B) Levels of TRX were less in U87 than in SVG cells.
Table 2
Antioxidants in the host cell react with the elevated oxidants
2O2
+ 2H+ !SOD H2O2+ O2
2H2O2 !CAT 2H2O + O2
H2O2+ 2GSH !GPx 2H2O + GS-SGa
2GSH + R-O-OH !GPx GS-SG + H2O + R-OHa
SOD, superoxide dismutase; CAT, catalase; GPx, glutathione peroxidase.
a GS-SG, the product of these reactions, is converted to GSH (which does no
damage to the host cell) under the effect of glutathione reductase.
Y. Zhang et al. / International Journal of Infectious Diseases 24 (2014) 30–3632triphosphate (ATP) and mitochondrial membrane potential,
leading to the release of cytochrome c from the mitochondria
and activation of caspase 3, causing neuronal apoptosis.34 Yang
et al. reported the activation of caspases 3, 8, and 9 in JEV-infected
human pro-monocyte HL-CZ cells, which led to caspase-dependent
apoptosis.35 However, the overproduction of O2
 appears to non-
selectively impair the physiological functions of host cells,
regardless of infection, even though it suppresses viral replication
in situ.
NO and its toxic metabolite peroxynitrite are recognized as
important mediators of neuronal injury. NO levels are elevated in
the cerebrospinal ﬂuid of human JE patients.36 Consistent with
this, Liao et al. found that JEV infection induced the generation of
NO in rat cortical glial cells.32 A subsequent study then revealed
that NO levels were increased in acute JE rat models.18 JEV induces
the expression of iNOS, which is thought to be a key mediator in the
host innate immune response.
3. Signaling mechanisms of JEV infection in oxidative stress
The molecular pathogenesis of JE remains unclear, although
several potential mechanisms have been reported. JEV replication
in human pro-monocyte cells has been shown to induce time-
dependent apoptosis. In addition, it has been shown that the
downregulation of thioredoxin and the upregulation of ROS is
involved in the apoptosis induced by the oxidative stress response
pathway.37 JEV infection causes increased intracellular ROS
production and activation of ASK1-ERK/p38 MAPK signaling, both
of which are associated with JEV-induced apoptosis.35 Matrix
metalloproteinase 9 (MMP-9) leads to disruption of the BBB and
also contributes to the neuroinﬂammatory responses in many
neurological diseases. Tung et al. reported MMP-9 to be over-
expressed in the brains of rats with neurodegenerative diseases,
which was associated with a chronic inﬂammatory process and the
above signaling pathways. In addition, they observed the activa-
tion of the p42/p44 MAPK and the c-Jun NH(2)-terminal kinases 1/
2 (JNK1/2) pathways in response to MMP-9 expression.38,39 Finally,
treating cells with H2O2 elicited an inﬂammatory response
involving the NF-kB signaling pathway.40,41 Therefore, there are
many different potential sources of ROS in JEV-infected host cells,
many of which are capable of inﬂuencing, or being inﬂuenced by,
NF-kB activity. JEV infection is also associated with microglial
activation, resulting in the production of proinﬂammatory
cytokines including IL-1b and IL-18, which is mediated by ROS
production.42
The oxidation of proteins is widely viewed as a signature of
irreversible damage, and cellular-degradation pathways operate to
remove such proteins. Ubiquitination is generally involved in
protein degradation pathways. Ubiquitin is a small polypeptide
that covalently attaches to proteins, either singly or in the form of
polymeric chains. In the reverse process, deubiquitinase enzymes
(DUBs) disassemble ubiquitin chains and strip them from their
substrate proteins, thus rescuing proteins from ubiquitin-depen-
dent degradation pathways.43 Widespread inhibition of DUBs can
be caused by excess ROS generation, but this can be readily
reversed by an excess of a reducing agent such as dithiothreitol.41
Zhang et al. performed a SILAC-based quantitative proteomic study
of JEV-infected HeLa cells and found that the JEV infection-induced
host response was coordinated primarily by the immune response,
the ubiquitin–proteasome system, the intracellular membrane
system, and lipid metabolism-related proteins.44 Expression of
interferon-stimulated gene 15 (ISG15), a ubiquitin-like protein,
was found to be rapidly induced by interferon-a/b (IFN-a/b), and
ISG15 conjugation to target proteins was associated with the
antiviral immune response.45 Hsiao et al. reported that ISG15
overexpression signiﬁcantly reduced the JEV-induced cytopathiceffect and inhibited JEV replication. Furthermore, ISG15 over-
expression increased the phosphorylation of interferon regulatory
factor-3 (IRF-3, Ser396), the Janus/just another kinase-2 (JAK2,
Tyr1007/1008), and signal transducers and activators of the
transcription 1 (STAT1, Tyr701 and Ser727) in JEV-infected cells.
ISG15 overexpression also induced the translocation of the
transcription factor STAT1 to the nucleus and activated the
expression of STAT1-dependent genes including IRF-3, IFN-b, IL-
8, protein kinase R (PKR), and 20,50-oligoadenylate synthetase
(OAS), both before and after JEV infection.46 These data reveal that
ubiquitination is involved in JEV infection, but the speciﬁc
mechanism is unclear.
4. The effects of changes in antioxidants on JEV infection
Reducing conditions are normally maintained within the cell by
antioxidant molecules. The antioxidant system is classiﬁed into
two types: an enzyme system including SOD, catalase (CAT), and
glutathione peroxidase (GPx), and other molecules including
glutathione (GSH), N-acetylcysteine (NAC), and selenium.47 In
addition, dietary micronutrients also contribute to the antioxidant
defense system including b-carotene, vitamin C, and vitamin E.
Water-soluble molecules, such as vitamin C, are potent radical
scavenging agents in the aqueous phase of the cytoplasm, whereas
lipid soluble antioxidants, such as vitamin E and b-carotene, act as
antioxidants within lipid environments.48 Selenium, copper, zinc,
and manganese are also important elements, since they act as
cofactors for antioxidant enzymes.49 In order to avoid harmful
effects caused by oxidants, antioxidants in the host cell react with
elevated oxidants and superoxides in several ways under normal
conditions (Table 2).
4.1. SODs and CAT
SODs are metal-containing proteins that catalyze the removal
of superoxide, generating water peroxide as the ﬁnal product of
dismutation. Three major isoforms of SODs have been identiﬁed.
The copper–zinc SOD (CuZn-SOD) isoform is present in the
cytoplasm, nucleus, and plasma. In contrast, the manganese SOD
(Mn-SOD) isoform is primarily located in mitochondria. Finally,
iron SOD (Fe-SOD) is mainly found in the plastids of plants and
prokaryotes.50 CAT is a family of heme-containing enzymes that
convert H2O2 to water and O2. They are predominantly localized in
peroxisomes, although expression can also be detected in the
mitochondria and endoplasmic reticulum.48 Therefore, intracellu-
lar H2O2 cannot be eliminated unless it diffuses into peroxisomes.
JEV infection has been reported to induce the generation of O2

and NO in rat cortical glial cells. Mn-SOD, but not CuZn-SOD, was
activated by JEV infection and this activation was blocked by
pyrrolidine dithiocarbamate. In addition, increased SOD activity
was apparent in cell lines that had been acutely or persistently
infected with JEV.32 These results suggest that cellular factors
regulating oxidative pathways might play roles in the cellular
response to JEV infection. In addition, Kumar et al. reported that
the activity of Mn-SOD in the striatum, cortex, thalamus, and
Y. Zhang et al. / International Journal of Infectious Diseases 24 (2014) 30–36 33midbrain was increased signiﬁcantly in JEV-infected rats, whereas
the activity of CAT, GPx, and GSH all decreased signiﬁcantly
compared with controls. Although Mn-SOD removes superoxide
radicals to combat oxidative stress, the simultaneous reduction of
CAT and GPx levels means that the H2O2 cannot be scavenged.
33
4.2. GSH and GPx
The most abundant cellular antioxidant is the cysteine-
containing tripeptide GSH, which prevents the oxidation of protein
thiol groups either directly by reacting with reactive species, or
indirectly through glutathione transferases.35,51 GPx remove H2O2
by coupling its reduction with the oxidation of GSH. GPx can also
reduce other peroxides such as fatty acid hydroperoxides. These
enzymes are present in the cytoplasm at millimolar concentrations
and also in the mitochondrial matrix.
Early in 1997, Garaci et al. reported that HIV-1 infection
induced a signiﬁcant decrease in intracellular reduced GSH levels
in human macrophages in vitro.52 Consistent with this, Nencioni
et al. demonstrated that redox changes during inﬂuenza A
infection were mediated by a depletion of GSH. They found that
GSH levels decreased during viral replication only in those cell
lines that efﬁciently produced mature inﬂuenza A virus.53 It is
possible that the concentration of GSH in the host cell has a
signiﬁcant effect on viral replication. In 2010, we showed that
infection with dengue virus serotype 2 (DENV2), also belonging to
the Flaviviridae family, resulted in a decrease in intracellular GSH.
In contrast, supplementing with GSH signiﬁcantly inhibited the
activation of NF-kB, resulting in decreased production of DENV2 in
HepG2 cells.54 In an additional study, the levels of GSH were
decreased signiﬁcantly in all the brain regions of rats after JEV
infection compared with controls.33 Therefore, growing evidence
has indicated that GSH might be valuable for the prevention of JEV
infection.
4.3. NAC
NAC is a precursor in the formation of the antioxidant
glutathione. Early in 1990, Staal et al. found that H2O2 promotes
the replication of HIV, but that antioxidants such as NAC have the
opposite effect.55 The group of Raung et al. reported that none of
the antioxidants tested, including NAC, protected N18 cells from
JEV-induced apoptotic and necrotic cell death.31 In addition,
Mishra et al. revealed that NAC was ineffective at protecting cells
from JEV-induced death.56 However, in both these studies, NAC
was able to change the intracellular redox status by scavenging
oxygen radicals.
5. Antioxidant agents inhibit JEV production
Along with the important role of oxidative stress in JEV
infection, a variety of antiviral agents have been studied toTable 3
Recently discovered antioxidative agents for JEV infection
Agent Target Active concentrat
Minocycline Inhibition of oxidative stress 20 mM 
Arctigenin Oxidative stress resulting from
microglial activation
Twice daily (10 m
the next 7 days
Fenoﬁbrate A peroxisome proliferator-activated
receptor alpha (PPARa) agonist
Mice: 100 mg/kg 
exposure
Cell: 40 mg/ml 1 h
JEV
Curcumin Decreasing the cellular reactive oxygen
species level
Treated with 1, 5,
curcumin for 8 h
JEV, Japanese encephalitis virus.evaluate their therapeutic efﬁcacy. Here we review four agents that
modulate different pathways (Table 3).
5.1. Minocycline
Minocycline, a semisynthetic tetracycline, is neuroprotective in
animal models against a number of acute CNS injuries, neurode-
generative diseases, and CNS infection.57 In addition to its
antioxidant properties, minocycline has been reported to have
many cellular effects, such as stimulating the expression and
activity of caspases and nitric oxide synthase, reactive microgliosis,
and the induction of the anti-apoptotic protein Bcl-2.58–60
Mishra et al. reported that minocycline inhibits JEV-induced
free radical generation in mouse neuroblastoma N2a cells. They
measured lactate dehydrogenase (LDH) activity, ROS levels, and
mitochondrial membrane potential and found that 20 mM
minocycline inhibited ROS production and neuronal death. There
was a signiﬁcant increase in the expression of phospho-NF-kB,
heat-shock protein 70 (HSP-70), phospho-JNK, and phospho-p38
MAPK in JEV-infected mice; however, treatment with minocycline
reduced this expression signiﬁcantly. The ratio of Bax/Bcl-2 was
also decreased signiﬁcantly by treatment with minocycline in JEV-
infected N2a cells.56 These ﬁndings suggest that minocycline
reduces the neuronal damage induced by JEV infection in neuronal
cell culture models, in part by inhibiting oxidative stress.
5.2. Arctigenin
Arctigenin is a plant lignan with antioxidant, anti-inﬂammato-
ry, and antiviral activities that modulates multiple cellular
machineries.61–63 It has been described as a biologically active
lignan, with potent anti-HIV and anti-inﬂuenza virus effects.64–66
Arctigenin has been found to confer complete protection to
animals infected with JEV and signiﬁcantly reduce morbidity.
Treatment with arctigenin increased the levels of SOD1, but
signiﬁcantly reduced the levels of NO and iNOS in the JEV-infected
mouse brains; this abrogated microglial activation and the
induction of proinﬂammatory cytokines. JEV infection upregulated
the induction of several stress-associated proteins, and treatment
with arctigenin signiﬁcantly reduced the level of these proteins in
infected animals. In particular, the expression of phospho-p38
MAPK, phospho-c-Jun, HSP-70, phospho-ERK1/2, and phospho-Akt
were decreased. In vitro, arctigenin treatment was found to reduce
viral titers and decrease the intracellular viral load in JEV-infected
N2a cells. In vivo and in vitro experiments clearly revealed that
arctigenin reduced viral load and replication, as well as inhibiting
the neuronal death, secondary inﬂammation, and oxidative stress
that resulted from microglial activation.67 Therefore, the antiviral,
neuroprotective, anti-inﬂammatory, and antioxidant effects of
arctigenin successfully reduced the severity of JEV-induced
disease.ion Model system Ref.
Mouse neuroblastoma (N2a cells) 56
g/kg body weight) for BALB/c mice 67
4 days prior to JEV
 prior to exposure to
BV-2 microglial cell line and BALB/c
mouse models
71
 and 10 mM doses of Neuro2a cell line 73
Y. Zhang et al. / International Journal of Infectious Diseases 24 (2014) 30–36345.3. Fenoﬁbrate
Fenoﬁbrate is an agonist of peroxisome proliferator-activated
receptor a (PPARa) and so it stimulates the expression of the
neuroprotective genes that trigger both antioxidant and anti-
inﬂammatory responses. It increases the transcription of a number
of genes including CuZn-SOD, GPx, glutathione reductase (GR),
glutathione-S transferase (GST), and CAT, but inhibits the
transcription of NF-kB, STATs, activator protein 1 (AP1), and
nuclear factor of activated T cells (NFAT) signaling pathways.68,69
PPARa activation by fenoﬁbrate confers neuroprotection in
various CNS disorders, such as traumatic brain injury and
Parkinson’s disease.69,70 Sehgal et al. examined the neuroprotective
effects of fenoﬁbrate using both in vivo and in vitro models of JEV
infection. In JEV-infected BALB/c mice, pretreatment with fenoﬁ-
brate for 4 but not 2 days reduced mortality by 80%. In addition, brain
leukotriene B4 (LTB4) levels decreased concomitantly with the
induction of Cyp4f15 and 4f18, which catalyze the detoxiﬁcation of
LTB4 via hydroxylation. They also found that fenoﬁbrate abrogated
JEV-mediated microglial activation and the release of inﬂammatory
mediators in the BV-2 microglial cell line. Pretreatment with
fenoﬁbrate for 4 days signiﬁcantly decreased the viral titers in the
culture medium of BV-2 cells infected with JEV.71 Thus fenoﬁbrate, a
PPARa agonist that is commonly used as a hypolipidemic drug,
could potentially be used for treatment or as prophylaxis during JE
epidemics to reduce mortality and morbidity.
5.4. Curcumin
Curcumin is a naturally occurring phenolic compound
extracted from the rhizome of Curcuma longa L.72 It has been
reported to have anti-inﬂammatory, antioxidant, and anti-prolif-Figure 1. Mechanistic basis and multi-level regulation of antioxidant-related pathways in
ROS and downregulation of antioxidant, which is involved in the apoptosis induced by th
MAPK, and DUBs signaling, which is associated with JEV-induced apoptosis. (B) Treatm
increases the transcription of a number of genes including SOD, GPx, GR, HSP-70, GST,
pathways. Antioxidants reduce the viral load and replication, as well as inhibiting the neu
activation. Abbreviations: AP1, activator protein 1; CAT, catalase; Cyt c, cytochrome 
reductase; GST, glutathione-S transferase; HSP-70, heat-shock protein 70; NF-kB, nuc
activators of transcription; NFAT, nuclear factor of activated T cells; SOD, superoxide derative properties and modulates multiple cellular machineries by
inhibiting several intracellular signaling pathways including
MAPK, PI3K/AKT, and pNF-kB.63
JEV-infected N2a cells were treated with varying doses of
curcumin in vitro. Cell viability was increased and apoptosis was
decreased signiﬁcantly in curcumin-treated cells compared with
cells infected with only virus. Curcumin increased expression of
SOD-1 and HSP-70, but decreased cellular ROS levels; this helped
ameliorate the oxidative stress and apoptosis caused by a variety of
factors. Curcumin restored the integrity of cellular membranes by
decreasing the expression of pro-apoptotic signaling molecules
and modulating the cellular levels of stress-related proteins such
as pJNK, phospho-p38 MAPK, pERK-1/2, and pNF-kB. Curcumin
also reduced the production of infectious viral particles from
previously infected neuroblastoma cells by dysregulating the
ubiquitin–proteasome system.73 These studies revealed that
curcumin has an outstanding safety proﬁle and substantial
potential antiviral effects.
6. Conclusions and perspectives
Unfortunately, no speciﬁc antiviral agents are currently
approved for the treatment of JEV infection in human patients.
An increasing number of drug-resistant viruses have emerged
due to the abuse of traditional antiviral drugs. Great efforts are
being made in laboratories worldwide to identify an effective,
safe, and readily available therapy to alleviate JEV. In this
review, we have summarized the relationship between oxida-
tive stress, JEV infection, and a variety of antioxidants as
antiviral agents to evaluate their therapeutic efﬁcacy (Figure 1).
Antiviral therapies based on antioxidants are promising
potential targets and it is likely that more antioxidants will Japanese encephalitis virus (JEV) infection. (A) JEV infection causes upregulation of
e oxidative stress response pathway. JEV infection activates p-NF-kB, p-JNK, p-p38
ent with antioxidants, such as minocycline, arctigenin, fenoﬁbrate, and curcumin,
 and CAT, but inhibits the transcription of NF-kB, STATs, AP1, and NFAT signaling
ronal death, secondary inﬂammation, and oxidative stress resulting from microglial
c; DUBs, deubiquitinase enzymes; GPx, glutathione peroxidase; GR, glutathione
lear factor kappa B; ROS, reactive oxygen species; STATs, signal transducers and
ismutase.
Y. Zhang et al. / International Journal of Infectious Diseases 24 (2014) 30–36 35be identiﬁed with potential as therapeutic agents against JEV
infection. With many potential candidates based on antiox-
idants and the support of government and private funding, the
prospect of an effective antiviral or therapeutic compound for
the treatment of JEV is encouraging.
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